5-MeO-DMT for Personality & Trait Factors

3 papers and 0 clinical trials exploring 5-meo-dmt as a treatment for personality & trait factors.

CompoundTryptamine

5-MeO-DMT

A potent tryptamine psychedelic known for profound mystical experiences, currently under clinical investigation for TRD and anxiety.

Full 5-MeO-DMT profile

IndicationApproximately 10 million adults in the UK suffer from a personality disorder.

Personality & Trait Factors

Psychedelic research is increasingly examining the interplay between personality traits and therapeutic outcomes in various mental health conditions. Recent studies highlight how certain personality traits may influence the efficacy of psychedelic treatments, particularly in managing disorders like depression and anxiety.

Full Personality & Trait Factors profile

Academic Research

3 papers

Paywallindividual

Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and/or anxiety: a randomized, double-blind, placebo-controlled study

This Phase I clinical trial (n=36) of sublingual 5-MeO-DMT (6-12 mg weekly doses over four weeks) in adults with moderate to high anxiety/depression demonstrated good safety and tolerability with no significant adverse events, rapid absorption with peak plasma concentrations at 20 minutes, dose-dependent neurophysiological modulation without full psychedelic effects, and maintenance of normal cognitive and behavioral function.

Published: July 15, 2025
Journal: Neuropsychopharmacology
Authors: Beatriz, M., Millón, B., Noguera, L., Bruno, D., Vita, L., Zanino, M., Kassuha, D. E., Ortiz, J. E., Feresin, G. E., Díaz-Dellavalle, P., Orosco, L., Garcés, M. A., Diez, P., Albarracín, S. G., Bruno, M. A.

Paywallindividual

Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants

In this double-blind, placebo-controlled Phase 1 trial, intranasal BPL-003 (5‑MeO‑DMT benzoate) was well tolerated up to 12 mg and showed rapid absorption and elimination with dose‑proportional systemic exposure (Tmax ≈ 8–10 min; mean terminal half‑life <27 min) and negligible bufotenine formation. Pharmacodynamic effects scaled with plasma concentrations, producing profound, short‑lasting consciousness‑altering and mystical experiences—60% of participants had a complete mystical experience at 10–12 mg—supporting further clinical evaluation.

Published: April 14, 2024
Journal: Journal of Psychopharmacology
Authors: Rucker, J., Roberts, C. A., Seynaeve, M., Young, A. H., Suttle, B., Yamamoto, T., Ermakova, A. O., Dunbar, F., Wiegand, F.

Open Accessindividual

Cross-sectional associations between lifetime use of psychedelic drugs and psychometric measures during the COVID-19 confinement: A transcultural study

In a cross‑sectional online survey of 2,974 English, Portuguese and Spanish speakers during the first COVID‑19 lockdown, regular lifetime users of psychedelic drugs reported lower psychological distress and peritraumatic stress and greater perceived social support than occasional users and non‑users. They also scored higher on novelty‑seeking and self‑transcendence and lower on cooperativeness, suggesting either a protective effect of psychedelics or pre‑existing personality differences that predispose to regular use.

Published: June 16, 2021
Journal: Frontiers in Psychiatry
Authors: Bouso, J. C., Révész, D., Ona, G., Rossi, G. N., Rocha, J. M., Dos Santos, R. G., Hallak, J. E., Alcázar-Córcoles, M. A.

Clinical Trials

0 trials

No clinical trials have been tagged with both 5-MeO-DMT and Personality & Trait Factors yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all 5-MeO-DMT papers Search all Personality & Trait Factors trials Full 5-MeO-DMT profile Full Personality & Trait Factors profile

Company

Product

Legal